In its first-in-human Phase I clinical trial, SHR-4849, a new ADC that targets DLL3, showed good antitumor activity and a controllable safety profile in patients with recurrent small cell lung cancer(r-SCLC) who had previously undergone conventional therapy. The gene discussed is DLL3; the disease is small cell lung carcinoma.